Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments 中文版
18 Apr, 2019 (Thursday)

            
SSY GROUP(2005)
Analysis:
According to the operating results of SSY Group (2005) for the three months ended 31 March 2019, the turnover of the Group slightly decreased by 1.6% as compared with the same period of 2018 to HK$1.082 billion, mainly because RMB depreciated by about 5.7% when translated into Hong Kong Dollars for the three months ended 31 March 2019. In terms of RMB, the turnover of the Group actually increased by 4.3% to RMB925 million. The Group also announced that it has obtained a total of 6 approvals for drug productions and registrations from the National Drug Administration of China, in which three are for Peritoneal Dialysis Solution and three are for Low Calcium Peritoneal Dialysis Solution. (I do not hold the above stock)
Strategy:
Buy-in Price: $7.40, Target Price: $8.20, Cut Loss Price: $6.90


UM HEALTHCARE(2138)
Analysis:
The Group is principally engaged in the provision of medical, quasi-medical, traditional beauty services, the sale of skincare and beauty products. The Group announced an increase of no less than 26% in sales volume (being the total sales volume generated from contracted sales entered into, and all products and services offered by the Group) for the year ended 31 March 2019 as compared with last year. It is believed that such increase was mainly due to the Group`s elevated level of services and expanded service mix leading to the increase in the customers` purchase, in particular purchases from the PRC customers, for medical services that the Group is offering. The Group entered into agreement with “Tencent Doctorwork”, a subsidiarity of Tencent last year, for jointly establishing primary care clinics in Hong Kong and co-invest and developing IT system to connect medical services across the PRC and Hong Kong. Besides, they plan to establish a total of 20 clinics in Hong Kong over the next three years. Currently, two clinics under the brand “企鵝醫生” has commenced operation in Hong Kong. In addition, thanks to the promotion of the “Greater Bay Area”, the medical tourism becomes a growth driver. In the future, the Group will continue the expansion of their medical aesthetic clinic in first-tier and selected second-tier cities in the PRC, and explore acquisition targets as well as partnership opportunities with local medical players in the PRC.
Strategy:
Buy-in Price: $5.00, Target Price: $6.80, Cut Loss Price: $4.50


Sprix(7030.JT)
Founded in 1997, SPRIX, Ltd. offers online educational services and individual guidance services. The Company provides educational software that enables user to learn various courses and programs. SPRIX offers services in Japan. For its earnings report of first quarter of 2019 fiscal year announced on 12th February, 2019, the revenue, operating income & net income of Sprix were ¥7.525 billion, ¥1.819 billion and ¥1.171 billion respectively. Its core business, individual guidance business has grown at 15.9% year over year while its number of the FC Classroom raised at 71.4%. For its full-year earning guidance, the revenue, operating income & net income of Sprix are projected upward to rise 9.1% to ¥11.401 billion, 0.3% to ¥2.474 billion & 1.9% to ¥1.595 billion year over year. On 27th February, 2019, Sprix announced that a new company was established to develop and sell the online program learning material "QUREO" for primary school students. Since 2020, program education has become a compulsory subject of primary education, so domestic parents are highly anticipated towards Sprix related education products. Recommend to buy at ¥2234, target price ¥2763, cut loss if drop below ¥2030.



Jonjee Hi-Tech(600872.CH) - Condiment Business Grows Steadily with the Initially Set-up National Layout

Investment Summary

The Result Remains High While the Growth Rate Slows Down in H2

In 2018, JonjeE Hi-Tech recorded a revenue of RMB4,166 million, up by 15.4% yoy; a net profit attribute to shareholders of listed companies of RMB607 million, up by 34%, which was sharply slowed down compared with 61% in the H1 of last year. The shipment was decreased due to the relatively high base in the third quarter of last year and the typhoon in the third quarter of this year, which resulted in the flat net profit in the third quarter. The annual EPS was RMB0.76, and the result was slightly (5.6%) worse than our expectation. The weighted return on equity was 18.07%, up by 2.86 ppts yoy. The dividend per share was RMB0.23, with a dividend payout rate 30%.

Condiment Business Grows Steadily and Oyster Sauce and Cooking Wine Business Make highlight Achievements

The result of the Company's condiment sector maintained a steady growth, the annual revenue of Meiweixian was RMB3.85 billion, up by 10% yoy. Among the different product lines, the performance of two main categories of soy sauce and chicken powder grew steadily; among the small category of products, the sales of cooking oil grew rapidly, the oyster sauce and cooking wine business made achievements. The revenue of soy sauce increased by 8% to RMB2.59 billion, its sales volume increased 7.8%, and its unit price increased slightly. The revenue of chicken powder reached RMB440 million, up by 7.24% yoy, the sales volume increased by 7.27% yoy, and its unit price remained basically the same. The revenue of cooking oil increased by 16% to RMB320 million, the sales volume increased by 23% annually, and its unit price decreased. The revenue of oyster sauce increased sharply by 42% to RMB140 million, the sales volume increased by 39%, and its unit price increased slightly. The revenue of cooking wine and its sales volume increased sharply by 69% and 75% to RMB58 million and 9,986 tons, respectively.

During the period, the sales of the Company's commercial housing increased by RMB74 million, leading to an increase of 1.5 times to the revenue of real estate and service industries to RMB126 million, which also increased its performance.

Expense Rate and Cost Rate Increase and Decrease and the Whole Situation Remains Unchanged

In 2018, the Company's gross margin dropped slightly by 0.16 ppts to 39.1%, mainly due to the rapid growth of products with low gross margin such as oyster sauce, cooking oil, cooking wine and the increase of raw material prices. Due to the small scale, the gross margin of oyster sauce, sauce, vinegar and cooking wine was only half of that of Haitian Food. With the continuously production of new capacity in Yangxi Base, and the gradually emerged scale effect, the overall gross margin of condiment business will be expected to increase in the future.

The sales expense rate dropped by 1.46 ppts, mainly due to the slowdown in the growth of freight and business expenses and the reduction in advertising costs. The administration expense rate was basically flat, and the financial expense rate decreased by 0.37 ppts, mainly because the Company repaid part of some bank loans and the loan interest expenditure decreased accordingly. The Company restrained the impact caused by cost increasing to some extent by controlling cost and improving production efficiency.

Steady Progress Has Been Made in the Construction of Channels and National Layout Has Taken Shape

During the period, the Company continued to vigorously expand its sales channels, 18 blank prefecture-level cities and 178 distributors (90 in the H1 and 88 in the H2) were newly added. The total number of distributors reached 864, the development rate of prefecture-level cities was 77%, and the preliminary layout of export channels was completed. From the perspective of regional market development, in 2018, the revenue of condiments in the east, south, Midwest and north regions increased by 10%, 8%,12% and 18%, respectively. The growth of revenue in the Midwest and north regions was relatively high, and the growth of gross margin was steady, conforming the Company's regional development strategy of “steadily developing the southeast, focusing on the development of the north and the middle, accelerating the development of the southwest, and gradually promoting the development of the Northwest”. It is expected that the Company will have about 1,000 distributors by the end of 2019, and the distributors will preliminarily be distributed in all prefecture-level cities.

Investment Thesis

According to the annual report, 90,000 square meters of commercial housing in the real estate business of the Company will be sold in 2019, the inventory reached 23,000 square meters, and it's expected that the performance will be continuously increased. At present, the Company is striving to stand out from the second echelon of the industry and move closer to the first echelon, striving to record a sales revenue of more than RMB10 billion by 2023.We believe that China's condiment industry is entering a new stage featuring steady growth, restructuring, large-scale and high-quality. The Company's brand advantages are strong. Coupled with the expansion of capacity scale and pipeline and capital support, the Company will continue to be beneficial from consumption upgrading in the future.

We expected diluted EPS of the Company to RMB 0.93 and 1.14 of 2019/2020. And we accordingly gave the target price to 37.3, respectively 40/33x P/E for 2019/2020. "Cautiously Accumulate" rating maintained. (Closing price as at 16 April 2019)

Risk

Price war among peers

Raw material price increase

New business risk

Financials

Click Here for PDF format...




Recommendation on 18-4-2019
RecommendationCautiously Accumulate
Price on Recommendation Date$ 34.210
Suggested purchase priceN/A
Target Price$ 37.300
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+86 21 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2019 Phillip Securities (HK) Ltd. All Rights Reserved.